Archary, D., Rong, R., Gordon, M. L., Boliar, S., Madiga, M., Gray, E. S., Dugast, A. S., Hermanus, T., Goulder, P. J. R., Coovadia, H. M., Werner, L., Morris, L., Alter, G., Derdeyn, C. A., & Ndung'u, T. (2012). Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 433(2), 410-420. https://doi.org/10.1016/j.virol.2012.08.033
Archary, Derseree ; Rong, Rong ; Gordon, Michelle L. et al. / Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. In: Virology. 2012 ; Vol. 433, No. 2. pp. 410-420.
@article{0dd953c4175845138358b338e32db248,
title = "Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection",
abstract = "Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.",
keywords = "Binding antibodies, Chronic infection, HIV-1 subtype C, Neutralizing antibodies",
author = "Derseree Archary and Rong Rong and Gordon, {Michelle L.} and Saikat Boliar and Maphuti Madiga and Gray, {Elin S.} and Dugast, {Anne Sophie} and Tandile Hermanus and Goulder, {Philip J.R.} and Coovadia, {Hoosen M.} and Lise Werner and Lynn Morris and Galit Alter and Derdeyn, {Cynthia A.} and Thumbi Ndung'u",
note = "Funding Information: This work was supported by the Howard Hughes Medical Institute, the Hasso Plattner Foundation and the South African Department of Science and Technology/National Research Foundation Research Chair Initiative . D.A. was supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program funded by the Fogarty International Center, NIH (grant #D43TW00231 ) and NIH R01 AI-58706 to C.A.D.",
year = "2012",
month = nov,
day = "25",
doi = "10.1016/j.virol.2012.08.033",
language = "English",
volume = "433",
pages = "410--420",
journal = "Virology",
issn = "0042-6822",
number = "2",
}
Archary, D, Rong, R, Gordon, ML, Boliar, S, Madiga, M, Gray, ES, Dugast, AS, Hermanus, T, Goulder, PJR, Coovadia, HM, Werner, L, Morris, L, Alter, G, Derdeyn, CA & Ndung'u, T 2012, 'Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection', Virology, vol. 433, no. 2, pp. 410-420. https://doi.org/10.1016/j.virol.2012.08.033
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. / Archary, Derseree
; Rong, Rong; Gordon, Michelle L. et al.
In:
Virology, Vol. 433, No. 2, 25.11.2012, p. 410-420.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection
AU - Archary, Derseree
AU - Rong, Rong
AU - Gordon, Michelle L.
AU - Boliar, Saikat
AU - Madiga, Maphuti
AU - Gray, Elin S.
AU - Dugast, Anne Sophie
AU - Hermanus, Tandile
AU - Goulder, Philip J.R.
AU - Coovadia, Hoosen M.
AU - Werner, Lise
AU - Morris, Lynn
AU - Alter, Galit
AU - Derdeyn, Cynthia A.
AU - Ndung'u, Thumbi
N1 - Funding Information:
This work was supported by the Howard Hughes Medical Institute, the Hasso Plattner Foundation and the South African Department of Science and Technology/National Research Foundation Research Chair Initiative . D.A. was supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program funded by the Fogarty International Center, NIH (grant #D43TW00231 ) and NIH R01 AI-58706 to C.A.D.
PY - 2012/11/25
Y1 - 2012/11/25
N2 - Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.
AB - Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.
KW - Binding antibodies
KW - Chronic infection
KW - HIV-1 subtype C
KW - Neutralizing antibodies
UR - http://www.scopus.com/inward/record.url?scp=84867193794&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2012.08.033
DO - 10.1016/j.virol.2012.08.033
M3 - Article
C2 - 22995189
AN - SCOPUS:84867193794
SN - 0042-6822
VL - 433
SP - 410
EP - 420
JO - Virology
JF - Virology
IS - 2
ER -
Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES et al. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25;433(2):410-420. doi: 10.1016/j.virol.2012.08.033
